GENEVANT SCIENCES HOLDINGS LIMITED

Active London

Activities of other holding companies n.e.c.

2 employees website.com
Activities of other holding companies n.e.c.
G

GENEVANT SCIENCES HOLDINGS LIMITED

Activities of other holding companies n.e.c.

Founded 5 Jan 2018 Active London, United Kingdom 2 employees website.com
Activities of other holding companies n.e.c.

Previous Company Names

VANTAGE POINT THERAPEUTICS HOLDINGS LIMITED 6 Mar 2018 — 4 Apr 2018
RANAVANT HOLDINGS LIMITED 5 Jan 2018 — 6 Mar 2018
Accounts Submitted 3 Dec 2025 Next due 31 Dec 2026 8 months remaining
Confirmation Submitted 13 Jan 2026 Next due 18 Jan 2027 8 months remaining
Net assets £238K £181K 2024 year on year
Total assets £315K £214K 2024 year on year
Total Liabilities £77K £32K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

7th Floor 50 Broadway London SW1H 0DB United Kingdom

Website

www.example.com

Full company profile for GENEVANT SCIENCES HOLDINGS LIMITED (11134297), an active company based in London, United Kingdom. Incorporated 5 Jan 2018. Activities of other holding companies n.e.c.. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2018–2024)

Cash in Bank

£23.25k

Decreased by £3.20k (-12%)

Net Assets

£238.11k

Increased by £181.40k (+320%)

Total Liabilities

£76.88k

Increased by £32.22k (+72%)

Turnover

N/A

Employees

2

Debt Ratio

24%

Decreased by 20 (-45%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

4 Allotments 4 Shares £375k Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
17 Mar 20251$120k$120k
6 Mar 20231$100k$100k
30 Mar 20221$80k$80k
29 Mar 20191$75k$75k

Officers

Officers

1 active 2 resigned
Status
Vistra Cosec LimitedCorporate-secretaryUnknownUnknown5 Jan 2018Active

Shareholders

Shareholders (1)

Genevant Sciences Ltd
100.0%
20,564

Persons with Significant Control

Persons with Significant Control (1)

1 Active

Roivant Sciences Ltd.

Bermuda

Active
Notified 1 Oct 2021
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

GENEVANT SCIENCES HOLDINGS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
10 Apr 2026OfficersChange to director Ms Emma Carys Price on 2026-04-01
31 Mar 2026OfficersChange Corporate Secretary Company With Change Date
13 Jan 2026Confirmation StatementConfirmation statement made on 2026-01-04 with updates
23 Dec 2025OfficersTermination of Jason Antony Reader as director on 2025-12-18
23 Dec 2025OfficersAppointment of Ms Chiara Bonetti as director on 2025-12-18
10 Apr 2026 Officers

Change to director Ms Emma Carys Price on 2026-04-01

31 Mar 2026 Officers

Change Corporate Secretary Company With Change Date

13 Jan 2026 Confirmation Statement

Confirmation statement made on 2026-01-04 with updates

23 Dec 2025 Officers

Termination of Jason Antony Reader as director on 2025-12-18

23 Dec 2025 Officers

Appointment of Ms Chiara Bonetti as director on 2025-12-18

Recent Activity

Latest Activity

Change to director Ms Emma Carys Price on 2026-04-01

2 weeks ago on 10 Apr 2026

Change Corporate Secretary Company With Change Date

3 weeks ago on 31 Mar 2026

Confirmation statement made on 2026-01-04 with updates

3 months ago on 13 Jan 2026

Termination of Jason Antony Reader as director on 2025-12-18

4 months ago on 23 Dec 2025

Appointment of Ms Chiara Bonetti as director on 2025-12-18

4 months ago on 23 Dec 2025